Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 311Carcinoma, Non-Small-Cell Lung 282Prostatic Neoplasms 160Colorectal Neoplasms 155Carcinoma, Hepatocellular 144Neoplasms 134Leukemia, Myeloid, Acute 132Lung Neoplasms 115Squamous Cell Carcinoma of Head and Neck 108Triple Negative Breast Neoplasms 102Multiple Myeloma 102Recurrence 99Pancreatic Neoplasms 94Stomach Neoplasms 93Ovarian Neoplasms 87Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Precursor Cell Lymphoblastic Leukemia-Lymphoma 68Esophageal Neoplasms 67Uterine Cervical Neoplasms 66Melanoma 65Brain Neoplasms 65Rectal Neoplasms 62Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 57Lymphoma 55Myelodysplastic Syndromes 54Esophageal Squamous Cell Carcinoma 54

Interventions

remdesivir 1Suspensions 1Specimen Handling 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Respiratory Syncytial Virus Infections × Clear all
NCT06817889 2026-06-03

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled

Autoimmune Diseases, Respiratory Syncytial Virus Infections

NCT06597916 2024-11-27

RSV Vaccination in Immunocompromised Patients.

Medical University of Vienna

Phase 2 Recruiting
200 enrolled

Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡